N/A N=25 Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,260,576 Improving Anticoagulation Control in VISN 1
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
Phase 2 N=20 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
Heparin-induced Thrombocytopenia Type II
Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants
N/A N=26 Strategies for Anticoagulation During Venovenous ECMO
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
N/A N=132 Anticoagulation Therapy in the Very Old
Atrial Fibrillation
Primary: Number of Patients Experiencing Stroke — 2; 2; 0 Participants
Phase 2 N=14 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
N/A N=200 Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Management of Anticoagulation
Primary: Mean Percentage of Time in Therapeutic Range — 48; 53 percentage of time — p=0.20
N/A N=72 Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
Anticoagulants
Primary: The Short-form Adherence to Refills and Medications Scale (ARMS) — 9.6; 9.4; 8.5; 9.3 score on a scale
Phase 2 N=250 Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
Atrial Fibrillation · Heart Valve Diseases · Venous Thrombosis
Primary: Primary Outcome Measure: Time in Therapeutic Range — 74.1; 71.6 percentage of time
N/A N=191 Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
Atrial Fibrillation · Hemorrhage
Primary: Proportion of Subjects With Index Event Safety Outcomes (Resolved / Recovery Ongoing / Deceased) at the Time of Their Hospital Discharge / Release. — 86.4; 7.3; 6.3…
N/A N=100 Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation
Bradycardia · Tachycardia · Atrial Fibrillation
Primary: Bleeding Complication — 0; 2; 0; 2 participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=73,989 Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
Non-valvular Atrial Fibrillation
Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…
N/A N=160 Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence
Atrial Fibrillation · Medication Adherence
Primary: Medication Adherence — 93.08; 89.52 percentage of doses recorded as taken — p=0.28
Phase 4 N=150 Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
Atrial Fibrillation · Catheter Ablation
Primary: Time to Ambulation — 480; 316 minutes — p=<0.001
Phase 4 N=101 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Dementia · Cognition Disorders · Cerebral Ischemic Events
Primary: Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist — 0; 0 Participants
Phase 3 N=56 Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
Coronary Artery Bypass Grafting · Postoperative Atrial Fibrilation · Stroke
Primary: Number of Participants With Strokes — 0; 0 participants — p=1.0
Phase 2 N=160 Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients
Atrial Fibrillation · Venous Thromboembolism · Ischemic Stroke
Primary: Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks — 48; 45 participants
N/A N=63 Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
Upper Gastrointestinal Bleeding
Primary: The Proportion of Randomized Patients That Complete a Brief Medication Review Phone Call at Week 5 — 7; 12; 8; 8 Participants
N/A N=12 Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban — 43; 51; 41; -5 days
N/A N=977 Randomized On-X Anticoagulation Trial
Heart Valve Disease
Primary: Thromboembolism — 4.86; 0.29; 2.43; 1.74 %/patient years
N/A N=148 PRescriptiOn PattERns Of Oral Anticoagulants
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
N/A N=333,664 Anticoagulant Utilization Pattern
Atrial Fibrillation
Primary: Description of the Characteristics of Anticoagulant Initiators — 3.41; 4.30; 3.59; 3.82 Scores on a scale
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
Phase 4 N=3,745 The Home INR Study
Atrial Fibrillation
Primary: Time to First Event (Death, Stroke, Major Bleed) — 0.0785; 0.0987; 0.1542; 0.1820 cumulative probability of event — p=0.14
N/A N=53,969 Medical Need of OAC Reversal
Atrial Fibrillation
Primary: The Number of Patients With Emergency Surgery and Major Bleeding Due to Fracture or Trauma. — 14; 35; 84 Number of Patients
Phase 3 N=602 Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
Atrial Fibrillation
Primary: Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K…
Phase 4 N=66 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Atrial Fibrillation
Primary: Coronary Artery Calcium (CAC) Score — 66; 31 units on a scale
Phase 4 N=154 Self-management of Low Molecular Weight Heparin Therapy
Thromboembolism
Primary: Drug Use Problems — 1.25; 0.86; 1.20; 1.17 scores on a scale
N/A N=20 Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
Left Sided Heart Failure · Left Ventricular Assist Device · Anticoagulant Therapy
Primary: Nomogram Feasibility — 136; 112; 136; 111 Surveys — p=.45